8-K: Dare Bioscience Faces Nasdaq Delisting After Failing to Meet Minimum Bid Price Requirement

Dare Bioscience, Inc. has received a delisting notice from Nasdaq after its stock price remained below $1.00 for an extended period, and the company plans to appeal the decision.

Summary

• Dare Bioscience received a notification from Nasdaq on January 17, 2024, stating that they did not meet the minimum bid price requirement of $1.00 per share for continued listing.
• The company's stock price had been below this threshold for 30 consecutive business days, triggering the delisting notice.
• Dare Bioscience intends to request a hearing before the Nasdaq Hearing Panel to appeal the delisting decision.
• The request for a hearing will temporarily halt the delisting process until the Panel makes a decision.
• Hearings are typically scheduled 30 to 45 days after the request, and decisions are usually issued within 30 days of the hearing.
• There is no guarantee that the company will be successful in its appeal or maintain its listing on the Nasdaq Capital Market.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and the uncertainty surrounding the appeal process. The company faces a significant risk of being delisted, which is unfavorable for investors.

Positives

• The company is taking action by requesting a hearing to appeal the delisting decision.
• The hearing request will temporarily prevent the delisting of the company's stock.

Negatives

• The company failed to maintain the minimum bid price of $1.00 per share for 30 consecutive business days.
• The company received a delisting notice from Nasdaq.
• There is no guarantee that the company will be successful in its appeal and maintain its listing on the Nasdaq Capital Market.

Risks

• The company faces the risk of being delisted from the Nasdaq Capital Market.
• The hearing process may not result in a favorable outcome for the company.
• The hearing and decision timeline could be shorter than expected, which may be unfavorable for the company.
• The company's stock price may be negatively impacted by the delisting notice and the uncertainty surrounding the appeal process.

Future Outlook

The company's future on the Nasdaq Capital Market is uncertain, pending the outcome of the hearing before the Nasdaq Hearing Panel. The company is seeking to maintain its listing but there is no guarantee of success.

Management Comments

• The company will timely request a hearing before the Panel.
• There can be no assurance that the Company will be successful at the hearing or that the Company will be successful in maintaining the listing of its common stock on The Nasdaq Capital Market.

Industry Context

This delisting notice highlights the challenges faced by smaller biotech companies in maintaining stock prices above minimum thresholds, especially in volatile market conditions. It is not uncommon for companies to face delisting notices, and the outcome of the appeal process is often uncertain.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges in maintaining their stock price above the minimum bid price required by exchanges like Nasdaq.
• Companies like Agenus Inc. and Cassava Sciences have also faced similar delisting risks in the past, highlighting the volatility and risk associated with the sector.
• The outcome of Dare Bioscience's appeal will be closely watched by other companies in the sector facing similar challenges.

Stakeholder Impact

• Shareholders face the risk of losing their investment if the company is delisted.
• The company's employees may experience uncertainty about their future employment.
• The company's reputation may be negatively impacted by the delisting notice.

Next Steps

• The company will request a hearing before the Nasdaq Hearing Panel.
• The Nasdaq Hearing Panel will review the company's appeal.
• The Panel will make a decision regarding the company's listing status.

Key Dates

Keywords

delisting, Nasdaq, minimum bid price, hearing, stock price, compliance, appeal, listing, Dare Bioscience